SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

Obsidian Therapeutics, Inc. (“Obsidian”) (NASDAQ:OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today reported financial results for the third quarter ended September 30, 2026…

OBX

Related stories